- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01263275
Trial of Transcranial Direct Current Stimulation (tDCS) for Depression
September 15, 2015 updated by: Colleen Loo, The University of New South Wales
Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) for Depression.
Among antidepressant treatments, ECT stands as the most effective in treating acute depression.
However, patient concerns with the cognitive side effects of ECT have encouraged the development of new and more focal forms of brain stimulation such as transcranial Direct Current Stimulation (tDCS).
However, not all patients may respond to this treatment in the way that it is currently administered and this has raised interest in finding alternative, possibly more optimal ways of administering tDCS.
This study will investigate whether tDCS stimulation using an alternative electrode montage has antidepressant effects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Randwick, Sydney, New South Wales, Australia, 2031
- Black Dog Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject meets criteria for a DSM-IV Major Depressive Episode.
- Total MADRS score ≥20.
- Subject has not responded to tDCS given with a standard montage OR subject is unable to receive tDCS with standard montage - for example, due to skin rash etc at site of electrode placement for standard montage.
Exclusion Criteria:
- Diagnosis (as defined by DSM-IV) of: any psychotic disorder (lifetime); eating disorder (current or within the past year); obsessive compulsive disorder (lifetime); post-traumatic stress disorder (current or within the past year); mental retardation.
- History of drug or alcohol abuse or dependence (as per DSM-IV criteria) within the last 3 months (except nicotine and caffeine).
- Inadequate response to ECT in the current episode of depression.
- Subject is on regular benzodiazepine medication which it is not clinically appropriate to discontinue.
- Subject requires a rapid clinical response due to inanition, psychosis or high suicide risk.
- Neurological disorder or insult, e.g., recent stroke (CVA), which places subject at risk of seizure or neuronal damage with tDCS.
- Subject has metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites.
- Female subject who is pregnant.
- Participants who are not fluent in English will not be included in the trial for safety reasons: a) It is usually not possible to have an interpreter reliably available every weekday for up to 4 weeks and it is not safe to give tDCS to a subject who cannot tell us immediately of any side effects; b) As this is a novel treatment, the study involves detailed neuropsychological testing for safety reasons. This testing cannot be effectively or validly completed by someone who is not fluent in English. Note that translation of the proposed tests into English has not been validated and that we cannot be confident that neuropsychological impairment would be detected using this method.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Active tDCS
|
Each tDCS session lasting continuously for 20 minutes at 2 mA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Montgomery Asberg Depression Rating Scale for Depression (MADRS).
Time Frame: 6 months
|
Baseline (pre-treatment), post 8, post 15 and post 20 tDCS sessions, and follow-up 1 week, 1 month, 3 months and 6 months post treatment
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (ACTUAL)
July 1, 2015
Study Completion (ACTUAL)
July 1, 2015
Study Registration Dates
First Submitted
December 7, 2010
First Submitted That Met QC Criteria
December 17, 2010
First Posted (ESTIMATE)
December 20, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 17, 2015
Last Update Submitted That Met QC Criteria
September 15, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10368
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depression
-
Johns Hopkins UniversityNot yet recruitingMajor Depression | Major Depression Moderate | Major Depression SevereUnited States
-
Technical University of MunichEnrolling by invitationMajor Depression Moderate | Major Depression SevereGermany
-
Stanford UniversityTerminatedMajor Depressive Disorder | Major Depressive Episode | Major Depressive Disorder, Recurrent | Major Depression Mild | Major Depression Moderate | Major Depression SevereUnited States
-
Hawler Medical UniversityCompleted
-
Centre Hospitalier Universitaire de BesanconH. Lundbeck A/SCompletedResistant Major DepressionFrance
-
Cybin IRL LimitedWorldwide Clinical TrialsRecruitingDepression | Major Depressive Disorder (MDD) | Depression - Major Depressive Disorder | Depression in Adults | Depression Disorders | Depression DisorderUnited States, Australia, United Kingdom, Germany, Greece, Poland, Ireland, Czechia
-
First Affiliated Hospital of Zhejiang UniversityCompleted
-
University of PittsburghCompletedPostpartum Major DepressionUnited States
-
Si TianmeiUnknownMajor Depression DisorderChina
-
The Hong Kong Polytechnic UniversityActive, not recruitingHealthy | Major Depression in RemissionChina
Clinical Trials on tDCS (Eldith DC-Stimulator (CE certified))
-
The University of New South WalesCompletedMajor DepressionAustralia
-
The University of New South WalesCompleted
-
Hospices Civils de LyonCompleted
-
The University of New South WalesCompletedHealthy Volunteers | Brain ExcitationAustralia
-
The University of New South WalesCompletedBipolar Disorder | Depressive Disorder, MajorAustralia
-
The University of New South WalesCompletedBipolar Disorder | Major Depressive DisorderAustralia
-
Ludwig-Maximilians - University of MunichCompletedTherapy Resistant Major DepressionGermany
-
Institut National de la Santé Et de la Recherche...Terminated
-
Pusan National UniversityUnknown
-
Centre d'Investigation Clinique et Technologique...Adep AssistanceCompleted